WPD Pharmaceuticals Inc.
WBIO
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver,... WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
